Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health
Frontiers in Nutrition · 09.06.2025 · 12
DOI: 10.3389/fnut.2025.1579957 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 09.06.2025. Verfasst von Esteban Ortiz-Prado und 10 weiteren Autor:innen. Beteiligte Einrichtung: One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Vitamin D₃ (cholecalciferol) is a fat-soluble secosteroid with essential roles in calcium-phosphorus metabolism, bone health, and an expanding range of extraskeletal processes. Upon synthesis in the skin via ultraviolet B exposure or ingestion from dietary sources, cholecalciferol is hydroxylated in the liver and kidneys to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D), which exerts pleiotropic effects through vitamin D receptor (VDR)-mediated genomic and non-genomic pathways. This narrative review synthesizes evidence on the systemic effects of high-dose cholecalciferol on bone health, metabolism, cardiovascular and immune function, and its emerging roles in neurological, gastrointestinal, reproductive, oncologic, and psychiatric disorders. High-dose vitamin D₃ has demonstrated benefits in specific populations, including improved bone mineral density, immune homeostasis, glycemic control, and reduced inflammation. In patients with chronic kidney disease, cystic fibrosis, and inflammatory bowel disease, targeted supplementation has been associated with clinical improvements. Preclinical models support calcitriol’s antiproliferative and neuroprotective functions, and its synergistic effects with chemotherapy, although large-scale randomized controlled trials (RCTs) have yielded mixed or inconclusive results, particularly in cancer, cardiovascular events, and cognitive decline. Methodological variability—such as inconsistent dosing regimens, baseline vitamin D status, and heterogeneous populations—limits definitive conclusions. While vitamin D supplementation is generally safe within recommended limits, excessive intake may cause hypercalcemia or nephrolithiasis, emphasizing the need for personalized strategies. Food fortification and targeted screening remain underutilized yet cost-effective public health interventions. Overall, vitamin D₃ represents a promising but complex therapeutic agent, necessitating further rigorously designed clinical trials to establish evidence-based guidelines for its use in diverse pathological conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- One Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito, Ecuador.
Zitieren
APA
Ortiz-Prado, E., Vasconez-Gonzalez, J., Izquierdo-Condoy, J. S., Suárez-Sangucho, I. A., Prieto-Marín, J. G., Villarreal-Burbano, K. B., Barriga-Collantes, M. A., Altamirano-Castillo, J. A., Borja-Mendoza, D. A., Pazmiño-Almeida, J. C., & Cadena-Padilla, M. P. (2025). Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health. Frontiers in Nutrition, 12. https://doi.org/10.3389/fnut.2025.1579957
Vancouver
Ortiz-Prado E, Vasconez-Gonzalez J, Izquierdo-Condoy JS, Suárez-Sangucho IA, Prieto-Marín JG, Villarreal-Burbano KB, et al. Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health. Frontiers in Nutrition. 2025;12. doi:10.3389/fnut.2025.1579957
BibTeX
@article{OrtizPrado2025,
author = {Ortiz-Prado, Esteban and Vasconez-Gonzalez, Jorge and Izquierdo-Condoy, Juan S and Suárez-Sangucho, Isaac A and Prieto-Marín, José Guillermo and Villarreal-Burbano, Karen Bereniss and Barriga-Collantes, Mateo Alejandro and Altamirano-Castillo, John Alexander and Borja-Mendoza, Domenic Anahi and Pazmiño-Almeida, Jean Carlo and Cadena-Padilla, María Paz},
title = {Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health},
journal = {Frontiers in Nutrition},
year = {2025},
volume = {12},
doi = {10.3389/fnut.2025.1579957}
}
EUVIMED